[
    [
        {
            "time": "2023-03-15",
            "original_text": "Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat",
            "features": {
                "keywords": [
                    "Incyte",
                    "Q4",
                    "Earnings Miss",
                    "Revenues Beat"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-03-15",
            "original_text": "The Zacks Analyst Blog Highlights: ExxonMobil, Merck, Danaher, Novartis and Expedia",
            "features": {
                "keywords": [
                    "Zacks Analyst Blog",
                    "ExxonMobil",
                    "Merck",
                    "Danaher",
                    "Novartis",
                    "Expedia"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "energy",
                    "healthcare",
                    "industrials",
                    "travel"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-03-15",
            "original_text": "The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial",
            "features": {
                "keywords": [
                    "Vanda",
                    "Q4 Results",
                    "Inovio",
                    "Debt Offering",
                    "Caladrius",
                    "Diabetes Drug",
                    "Flunks",
                    "Mid-Stage Trial"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2023-03-15",
            "original_text": "J&J and Novartis back cancer geneticist’s immunotherapy start-up",
            "features": {
                "keywords": [
                    "J&J",
                    "Novartis",
                    "cancer",
                    "geneticist",
                    "immunotherapy",
                    "start-up"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "J&J and Novartis back cancer geneticist’s immunotherapy start-up",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]